Biosimilarity
The FDA Perspective
Seiten
2023
CRC Press (Verlag)
978-1-032-65235-1 (ISBN)
CRC Press (Verlag)
978-1-032-65235-1 (ISBN)
The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.
Summary:
The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.
Features:
First comprehensive analysis based on new guidelines and approval packages of several biosimilars
Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.
Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines
Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies
Allow creation of a fast-to-market pathway to develop biosimilars
Summary:
The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.
Features:
First comprehensive analysis based on new guidelines and approval packages of several biosimilars
Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.
Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines
Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies
Allow creation of a fast-to-market pathway to develop biosimilars
Sarfaraz K. Niazi Ph.D, is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.
Current Status of Biosimilar Biological Products. The FDA Position. Biosimilarity Tetrahedron. Analytical and Functionality Similarity. Non-clinical Assessment. Clinical Pharmacology Assessment. Clinical Studies. Interchangeability Status. Comprehensive Presentation
| Erscheinungsdatum | 23.08.2024 |
|---|---|
| Verlagsort | London |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Gewicht | 1000 g |
| Themenwelt | Technik |
| ISBN-10 | 1-032-65235-7 / 1032652357 |
| ISBN-13 | 978-1-032-65235-1 / 9781032652351 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Lern- und Arbeitsbuch (mit digitalem Training zum Downloaden)
Buch (2024)
SecuMedia (Verlag)
CHF 43,95
Praxiswissen zu Schimmelpilzschäden in Gebäuden: Mikrobiologie, …
Buch | Hardcover (2024)
Reguvis Fachmedien (Verlag)
CHF 138,60
